8-K: Zomedica Reports 10% Revenue Growth in Q3 2024, Fueled by Diagnostics and PulseVet Sales

Zomedica's third quarter 2024 financial results show a 10% revenue increase to $7 million, driven by strong growth in both diagnostics and therapeutic device segments.

Summary

• Zomedica's revenue for the third quarter of 2024 reached $7 million, a 10% increase compared to the same period in 2023.
• The Diagnostics segment saw a 38% revenue increase, primarily due to the adoption of the TRUFORMA product line.
• The Therapeutic Device segment experienced a 9% revenue increase, with PulseVet sales rebounding.
• Consumable revenues grew by 6% to $4.8 million, while capital revenues increased by 21% to $2.2 million.
• Gross margin for the quarter was 72.3%, exceeding the company's expectations of 65% to 70%.
• The company's total cash used during the quarter was approximately $5.2 million, with a non-GAAP operating cash burn of approximately $4.0 million after adjustments.
• Zomedica's net loss for the quarter was $6.7 million, compared to a net loss of $0.5 million in the same period last year, which included a one-time gain of $2.2 million.
• Non-GAAP EBITDA loss was $4.8 million, or $4.3 million when adjusted for non-recurring items.
• The company had $77.8 million in cash, cash equivalents, and available-for-sale securities as of September 30, 2024.
• Zomedica has received a CE Mark for the TRUVIEW system, allowing sales of their entire product portfolio in Europe and other countries that accept the CE Mark.

Sentiment

Score: 5

Explanation: The document presents mixed results. While revenue growth and gross margin are positive, the increased net loss and operating expenses raise concerns. The international expansion and strong liquidity are encouraging, but the overall sentiment is neutral to slightly negative due to the increased losses.

Positives

• Zomedica achieved a 10% increase in revenue, demonstrating growth in the business.
• The Diagnostics segment showed significant growth of 38%, indicating strong market adoption of TRUFORMA products.
• The rebound in PulseVet sales contributed to a 21% increase in capital revenue.
• The company's gross margin of 72.3% exceeded expectations, showing efficient cost management.
• Zomedica has a strong liquidity position with $77.8 million in cash and securities.
• The CE Mark for TRUVIEW opens up new international markets for the company's products.
• International distribution agreements are expected to accelerate global adoption of Zomedica's portfolio.

Negatives

• The company reported a net loss of $6.7 million for the quarter, compared to a net loss of $0.5 million in the same period last year, which included a one-time gain.
• Operating expenses increased by 21% to $12.5 million, driven by increased R&D, sales and marketing, and general and administrative costs.
• Non-GAAP EBITDA loss was $4.8 million, compared to a loss of $0.3 million in the same period last year, which included a one-time gain.

Risks

• The company's net loss increased significantly compared to the same quarter last year, indicating potential challenges in achieving profitability.
• Increased operating expenses, particularly in R&D and sales and marketing, could impact future profitability.
• The company's ability to successfully integrate acquisitions and manage growth remains a risk.
• There are risks associated with the timing and results of commercialization efforts, including international expansion.
• The company faces competition from related products and must maintain and improve the quality of its products and services.
• The company's future performance is subject to various risks and uncertainties, including regulatory approvals, market acceptance, and economic conditions.

Future Outlook

Zomedica believes it is positioned to finish 2024 strong and move into 2025 from a position of strength, with plans to aggressively execute its strategy to drive the adoption of its portfolio globally. The company anticipates significant incremental revenue in 2025 and beyond due to international expansion.

Management Comments

• We are very pleased with our performance, highlighted by record third quarter revenue and a double-digit increase compared to last year, which demonstrates that the execution of our growth initiatives has continued to pay dividends.
• As expected, PulseVet capital sales rebounded during the third quarter bolstered by a full-strength sales team in the U.S. and continued positive utilization trends among existing customers.
• The strength of the PulseVet line was complemented by 38% growth in our Diagnostics segment, led by the continued adoption of our TRUFORMA product line.
• With these approvals in place, we are well positioned to leverage our international commercial infrastructure to add significant incremental revenue in 2025 and beyond.
• Based on the momentum we have created through the first three quarters of the year; we believe we are positioned to finish 2024 strong and move into 2025 from a position of strength.
• Supported by the strength of our balance sheet, we will continue to aggressively execute on our strategy to drive the accelerated adoption of our innovative portfolio on a global scale.

Industry Context

The veterinary health industry is experiencing growth, and Zomedica's focus on point-of-care diagnostics and therapeutics aligns with this trend. The company's international expansion efforts also reflect a broader industry move towards global markets.

Comparison to Industry Standards

• Zomedica's 72.3% gross margin is strong compared to many medical device companies, suggesting efficient cost management.
• The 38% growth in the diagnostics segment is notable, indicating a strong market reception for the TRUFORMA product line, which is a key differentiator for Zomedica compared to competitors.
• While the company is not directly comparable to large animal health companies like Zoetis or IDEXX, its focus on point-of-care solutions and international expansion is similar to the strategies of smaller, innovative players in the veterinary space.
• The company's liquidity of $77.8 million provides a solid foundation for future growth and expansion, which is a positive sign compared to other companies in the same stage of development.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss, but encouraged by the revenue growth and international expansion.
• Employees may benefit from the company's growth and expansion, but may also face challenges related to increased workload and responsibilities.
• Customers may benefit from the company's innovative products and services, but may also be impacted by any changes in pricing or availability.
• Suppliers may benefit from increased demand for their products and services, but may also face challenges related to meeting the company's needs.
• Creditors may be concerned about the increased net loss, but may also be reassured by the company's strong liquidity position.

Next Steps

• Zomedica will continue to execute its strategy to drive the adoption of its product portfolio.
• The company will leverage its international commercial infrastructure to add significant incremental revenue in 2025 and beyond.
• Zomedica will host a conference call on November 7, 2024, to discuss the Q3 2024 financial results.

Key Dates

Keywords

Zomedica, veterinary, diagnostics, therapeutics, PulseVet, TRUFORMA, TRUVIEW, revenue, gross margin, financial results, CE Mark, international expansion